Clinigen Group plc Issue of Equity (5457B)

TIDMCLIN

RNS Number : 5457B

Clinigen Group plc

08 October 2020

8 October 2020

Issue of Equity

Clinigen Group plc (AIM: CLIN, the "Group") announces that it has made an application for the admission to trading on AIM of 129,876 ordinary shares of 0.1 pence each in the Group (the "New Ordinary Shares"). These New Ordinary Shares have been issued to satisfy share options vesting under The 2017 Clinigen Group Sharesave Plan and rank pari passu with the existing shares of the Group. Admission to trading on AIM of the New Ordinary Shares is anticipated to occur on 13 October 2020.

At admission the issued share capital of the Group will consist of 133,028,647 ordinary shares, with no shares held in treasury. The total number of voting rights in the Group will therefore be 133,028,647. This figure may be used by shareholders as the denominator to determine if they are required to notify their interests in, or a change to their interests in, the Group under the Disclosure Guidance and Transparency Rules.

-Ends-

Contact details

 
 Clinigen Group plc                                Tel: [phone] 
 Shaun Chilton, Group Chief Executive Officer 
 Nick Keher, Group Chief Financial Officer 
 Matt Parrish, Head of Investor Relations 
 
 J.P.Morgan Cazenove - Nominated Adviser             Tel: [phone] 
  & Joint Broker                                             1000 
 James Mitford / Hemant Kapoor 
 
 RBC Capital Markets - Joint Broker                  Tel: [phone] 
                                                             4000 
 Marcus Jackson / Elliot Thomas 
 
 Instinctif Partners                                 Tel: [phone] 
                                                             2020 
 Melanie Toyne-Sewell / Phillip Marriage        Email: [e-mail] 
 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and the Asia Pacific region.

Clinigen now has over 1,150 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long term growth regions. The Group works with 21 of the top 25 pharmaceutical companies; interacting with over 18,000 registered users across 115 countries, shipping approximately 6.5 million units in the year.

For more information on Clinigen, please visit www.clinigengroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEFSIFEAESSEFS

(END) Dow Jones Newswires

October 08, 2020 11:00 ET (15:00 GMT)